Oryzon Genomics S.A. (BME:ORY)
Spain · Delayed Price · Currency is EUR 2.940
+0.022 (0.75%)
Aug 7, 2026, 12:56 PM CET
Oryzon Genomics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| - | 13.7 | 7.88 | 15.86 | 17.11 | 12.26 | |
Revenue Growth | - | 73.83% | -50.31% | -7.34% | 39.56% | 4.65% |
Cost of Revenue | - | 0.33 | 0.31 | 0.27 | 0.5 | - |
Gross Profit | - | 13.37 | 7.56 | 15.59 | 16.62 | 12.26 |
Selling, General & Admin | 5.7 | 5.31 | 3.59 | 3.75 | 3.39 | 4.3 |
Depreciation & Amortization Expenses | - | 0.16 | 0.15 | 0.17 | 0.18 | 0.16 |
Research & Development | 20.52 | - | - | - | - | - |
Other Operating Expenses | - | 14.57 | 8.43 | 16.7 | 18.93 | 15.77 |
Total Operating Expenses | 26.22 | 20.04 | 12.17 | 20.62 | 22.5 | 20.23 |
Operating Income | -26.22 | -6.7 | -4.6 | -5.03 | -5.89 | -7.97 |
Interest Income | - | - | - | - | 0.01 | 0.01 |
Interest Expense | - | -0.71 | -1.28 | -2.09 | -1.2 | -0.52 |
Other Non-Operating Income (Expense) | 23.46 | 0.01 | -0.04 | 0.34 | 0.04 | 0.32 |
Total Non-Operating Income (Expense) | 23.46 | -0.71 | -1.32 | -1.76 | -1.14 | -0.19 |
Pretax Income | -2.76 | -6.57 | -5.71 | -6.75 | -7.03 | -8.16 |
Provision for Income Taxes | - | -3.51 | -1.98 | -3.04 | -2.49 | -2.83 |
Net Income | -4.35 | -3.06 | -3.72 | -3.71 | -4.54 | -5.33 |
Net Income to Common | -5.26 | -3.06 | -3.72 | -3.71 | -4.54 | -5.33 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 77 | 74 | 63 | 77 | 53 | 53 |
Shares Outstanding (Diluted) | 77 | 74 | 63 | 77 | 55 | 53 |
Shares Change | 13.97% | 18.33% | -18.80% | 41.09% | 3.97% | 7.16% |
EPS (Basic) | -0.05 | -0.04 | -0.06 | -0.04 | -0.09 | -0.10 |
EPS (Diluted) | -0.05 | -0.04 | -0.06 | -0.04 | -0.09 | -0.10 |
EPS Growth | - | - | - | - | - | - |
Free Cash Flow | -4.94 | -13.4 | -5.79 | -0.57 | -1.92 | -3.8 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Per Share | -0.06 | -0.18 | -0.09 | -0.01 | -0.04 | -0.07 |
Gross Margin | - | 97.58% | 96.01% | 98.31% | 97.09% | 100.00% |
Operating Margin | - | -48.91% | -58.41% | -31.71% | -34.41% | -65.01% |
Profit Margin | - | -22.31% | -47.24% | -23.37% | -26.52% | -43.47% |
FCF Margin | - | -114.75% | -76.48% | -4.01% | -12.05% | -35.26% |
EBITDA | -22.48 | -5.58 | -4.28 | -4.4 | -5.32 | -6.87 |
EBITDA Margin | - | -47.76% | -56.46% | -30.65% | -33.37% | -63.68% |
EBIT | -26.22 | -6.7 | -4.6 | -5.03 | -5.89 | -7.97 |
EBIT Margin | - | -48.91% | -58.41% | -31.71% | -34.41% | -65.01% |
Effective Tax Rate | - | 53.47% | 34.76% | 45.07% | 35.46% | 34.72% |